On November 6, Hutchmed (China) announced that the latest and updated data from the ESLIM-01 Phase III study of surufatinib (suloplenib) and several studies of compounds independently developed by Hutchmed (China) will be presented at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, USA, from December 7 to 10, 2024, and at the 2024 European Society for Medical Oncology (ESMO) Asia Annual Meeting in Singapore from December 6 to 8, 2024.

Long-term safety and efficacy data from a follow-up, open-label subset study of the ESLIM-01 China Phase III study using surufatinib for the treatment of adult primary immune thrombocytopenia patients will be presented at the 2024 ASH Annual Meeting (NCT05029635). As of the data cutoff date of January 31, 2024, a total of 179 patients had received at least one dose of surufatinib treatment. In this subset study, 55.3% (99/179) of patients were still receiving treatment, with a median exposure time of 56.6 weeks.

The data from this follow-up subset study demonstrates that long-term treatment with surufatinib in adult primary immune thrombocytopenia patients in China can effectively increase and maintain platelet counts. In the overall population, 81% (145/179) of patients achieved an overall response, with a sustained response rate of 51.4% and a long-term sustained response rate of 59.8%. The median cumulative duration of platelet counts ≥50×10?/L was 38.9 weeks. Long-term treatment showed good tolerability, safety consistent with previous clinical studies, and no new safety signals were identified.